S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in

Ultragenyx Pharmaceutical Earnings Date, Estimates & History

+2.51 (+1.79 %)
(As of 02/24/2021 12:00 AM ET)
Today's Range
Now: $142.73
50-Day Range
MA: $146.10
52-Week Range
Now: $142.73
Volume255,665 shs
Average Volume472,444 shs
Market Capitalization$9.56 billion
P/E RatioN/A
Dividend YieldN/A


Ultragenyx Pharmaceutical has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 5th, 2021 based off prior year's report dates.

Ultragenyx Pharmaceutical Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Earnings Estimates

2021 EPS Consensus Estimate: ($4.03)
2022 EPS Consensus Estimate: ($2.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20215($1.25)($0.77)($1.02)
Q2 20215($1.35)($0.89)($1.03)
Q3 20215($1.41)($0.83)($1.00)
Q4 20214($1.45)($0.67)($0.98)
Q1 20221($0.90)($0.90)($0.90)
Q2 20221($0.75)($0.75)($0.75)
Q3 20221($0.59)($0.59)($0.59)
Q4 20221($0.49)($0.49)($0.49)

Ultragenyx Pharmaceutical (NASDAQ RARE) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
10/27/20209/30/2020($1.28)($1.13)($1.13)$55.18 million$81.47 millionTranscript
7/30/2020Q2 2020($1.56)($0.82)($2.05)$40.28 million$61.71 millionN/A
5/6/20203/31/2020($1.68)($1.91)($2.03)$36.74 million$36.31 millionTranscript
2/13/2020Q4 2019($1.61)($1.62)($1.66)$32.31 million$35.59 millionTranscript
11/5/2019Q3 2019($1.71)($1.96)($1.96)$28.88 million$25.80 millionTranscript
8/1/2019Q2 2019($1.73)($1.72)($1.98)$22.16 million$24.15 millionListen
5/6/20193/31/2019($1.73)($1.82)($1.82)$18.75 million$18.17 millionListen
2/19/201912/31/2018($1.74)($1.73)($1.73)$13.30 million$16.26 millionListen
11/5/20189/30/2018($1.94)($1.74)($1.74)$11.97 million$11.80 millionListen
8/2/2018Q2 2018($2.08)($1.06)($2.68)$5.63 million$12.79 millionN/A
5/7/2018Q1 2018($0.19)$0.62$0.62$56.58 million$10.68 millionN/A
2/20/2018Q4 2017($2.00)($2.27)($2.65)$0.75 million$2.41 millionTranscript
11/2/2017Q3 2017($1.87)($1.87)($1.87)$0.02 million$0.20 millionN/A
7/27/2017Q2 2017($1.73)($1.72)($1.72)$0.01 millionN/A
5/4/2017Q1 2017($1.70)($1.63)($1.63)$0.05 millionListen
2/16/2017Q4 2016($1.74)($1.75)($1.75)$0.05 million$0.01 millionN/A
11/7/2016Q3 2016($1.56)($1.64)($1.64)$7.60 million$0.11 millionListen
8/8/2016Q2 2016($1.47)($1.46)($1.46)$0.02 millionN/A
5/9/2016Q1 2016($1.29)($1.35)($1.35)N/A
2/25/2016Q4 2015($1.11)($1.42)($1.42)Listen
11/9/2015Q3 2015($0.85)($1.03)($1.03)N/A
8/13/2015Q2 2015($0.62)($0.83)($0.83)Listen
5/11/2015Q1 2015($0.54)($0.63)($0.63)Listen
3/25/2015Q4 2014($0.53)($0.52)($0.52)Listen
11/10/2014Q3 2014($0.45)($0.50)($0.50)N/A
8/11/2014Q2 2014($0.41)($0.45)($0.45)N/A
5/12/2014Q1 2014($0.38)($0.85)($0.85)Listen
3/24/2014Q4 2013($0.34)($4.98)($4.98)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.